Migration to Phase II implies that the results of the Phase I study met or exceeded the prospective client's expectations.
Prior to entering into the Phase II study, Radient and the prospective client typically agree upon and execute a negotiated Letter of Intent that, assuming the successful conclusion of the Phase II study, would provide the terms for establishing a long term exclusive supply or license agreement.
The objective of Phase II is to replicate Phase I results at a more significant scale in Radient's production plant. Phase II allows for optimization and expansion of targets to include primary and secondary product attributes necessary for market success. Specifically, Phase II tests involve processing a larger volume of the client's source material and delivery of the resulting target compound that meets the client's specifications in all regards to demonstrate the Radient's ability to process at commercial volumes. A Phase II will typically take 10 12 weeks to complete from receipt of the raw material through providing the prospective client with the Phase II report.
